Related Experiment Video
Updated: Aug 27, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
PI3K Inhibition for Squamous Cell Head and Neck Carcinoma
Antoine Desilets, Denis Soulières1
1From the Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada.
Abstract:
The phosphoinositide 3-kinase (PI3K) pathway is aberrantly activated in most head and neck squamous cell carcinomas, making it a prized target for targeted therapy development. Multiple PI3K inhibitors have been studied in early phase trials, with unfavorable risk-benefit ratios in molecularly unselected patient populations. Buparlisib, a potent pan-class I PI3K inhibitor, shows promising efficacy in combination with paclitaxel for advanced head and neck squamous cell carcinoma. Results of the phase III BURAN trial are awaited.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
The JAK-STAT Signaling Pathway
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

